Next, we obtained the best thresholds indicated by ROC curves for SKIDA1, LAMP5 and CSPG4 in acute leukemia (1.928, 2.874, and 0.401, respectively), AML (2.303, 6.002, and 1.371, respectively), and B-ALL (0.227, 5.846, and 0.305, respectively) to validate the predictive power of these genes as biomarkers in the TCGA (151 AML patients) and the French (173 B-ALL patients) cohorts. This evidence concerns the gene LAMP5 and acute leukemia.